GV joins $50 million round in Rome Therapeutics to research ‘junk DNA’ for cancer therapies

Rome Therapeutics, a biotechnology startup that’s using machine learning (ML) to explore the human genome and develop new treatments for…

author avatar

3 Followers
GV joins $50 million round in Rome Therapeutics to research ‘junk DNA’ for cancer therapies
http://feedproxy.google.com/~r/venturebeat/SZYF/~3/icgcU0DPK00/Rome Therapeutics, a biotechnology startup that’s using machine learning (ML) to explore the human genome and develop new treatments for cancer and autoimmune diseases, has launched out of stealth today with $50 million in series A funding from GV, Arch Venture Partners, and Partners Innovation Fund.Rome was incubated inside GV by CEO and cofounder Rosana Kapeller (M.D.,  » ....
Top
Comments (0)
Login to post.